Several neuropsychiatric and neurodegenerative disorders share stress as a risk factor and are more prevalent in women than in men. Corticotropin-releasing factor (CRF) orchestrates the stress response, and excessive CRF is thought to contribute to the pathophysiology of these diseases. We previously found that the CRF 1 receptor (CRF 1 ) is sex biased whereby coupling to its GTPbinding protein, Gs, is greater in females, whereas β-arrestin-2 coupling is greater in males. This study used a phosphoproteomic approach in CRF-overexpressing (CRF-OE) mice to test the proof of principle that when CRF is in excess, sex-biased CRF 1 coupling translates into divergent cell signaling that is expressed as different brain phosphoprotein profiles. Cortical phosphopeptides that distinguished female and male CRF-OE mice were overrepresented in unique pathways that were consistent with Gs-dependent signaling in females and β-arrestin-2 signaling in males. Notably, phosphopeptides that were more abundant in female CRF-OE mice were overrepresented in an Alzheimer's disease (AD) pathway. Phosphoproteomic results were validated by demonstrating that CRF overexpression in females was associated with increased tau phosphorylation and, in a mouse model of AD pathology, phosphorylation of β-secretase, the enzyme involved in the formation of amyloid β. These females exhibited increased formation of amyloid β plaques and cognitive impairments relative to males. Collectively, the findings are consistent with a mechanism whereby the excess CRF that characterizes stress-related diseases initiates distinct cellular processes in male and female brains, as a result of sex-biased CRF 1 signaling. Promotion of AD-related signaling pathways through this mechanism may contribute to female vulnerability to AD.
INTRODUCTION
Women are nearly twice as likely as men to suffer from stressrelated psychiatric disorders, such as depression and posttraumatic stress disorder. 1, 2 Alzheimer's disease (AD) is also more common in women than in men, and stress is a risk factor for this neurodegenerative disorder. [3] [4] [5] Hypersecretion of corticotropinreleasing factor (CRF), the neuropeptide that orchestrates the stress response, 6 has been implicated in the pathophysiology of these disorders. [7] [8] [9] Therefore, sex differences in CRF sensitivity may underlie the increased prevalence of stress-related neuropsychiatric diseases in females.
Our laboratory identified sex differences in CRF 1 receptor (CRF 1 ) coupling and trafficking that could be a molecular basis for the increased vulnerability of females to stress and stress-related pathology. 10 CRF 1 was more highly coupled to its GTP-binding protein (Gs) in female rats compared with male rats. 10 Moreover, in male rats, acute stress promoted CRF 1 association with β-arrestin-2, an effect not observed in female rats. Sex differences in CRF 1 coupling translated to physiological differences. 10 Specifically, locus coeruleus (LC)-norepinephrine neurons of female rats were sensitized to CRF and this sensitization was mediated by cyclic adenosine monophosphate (cyclic AMP) signaling, the signaling pathway activated by Gs. 10, 11 Sex differences in CRF 1 association with Gs and β-arrestin-2 and neuronal sensitivity to CRF were unrelated to circulating hormones. 10, 11 Finally, CRF 1 internalization, which requires CRF 1 -β-arrestin-2 association, was apparent only in male LC neurons following stress. 10 Collectively, these molecular sex differences render neurons of female rats more sensitive to CRF and less able to adapt to excess CRF through the compensatory mechanism of internalization. This was particularly apparent in CRF-overexpressing (CRF-OE) mice that model the CRF hypersecretion of stress-related psychiatric disorders. In these mice, only female LC neurons were hyperactive and CRF 1 was not internalized in female CRF-OE mice as it was in male CRF-OE mice. 12 In addition to its role in internalization, β-arrestin-2 links receptor activation to signaling cascades that are distinct from G-protein-induced signaling. 13, 14 Therefore, sex differences in CRF 1 coupling should translate to sex-biased CRF 1 signaling, favoring Gs-dependent signaling in females and β-arrestin-2 signaling in males. 15 Because β-arrestin-2 and Gs signaling pathways regulate protein phosphorylation dynamics, sex-biased CRF 1 signaling should give rise to sexually distinct profiles of protein phosphorylation when CRF 1 is activated. Through this mechanism, stressors could initiate sex-specific cellular effects that have different pathological consequences. Sex differences in CRF 1 signaling would be magnified when CRF is in excess, as modeled by CRF-OE mice. This study used a global phosphoproteomic approach with CRF-OE mice to test the hypothesis that the excessive CRF that occurs in stress-related disorders results in sexually distinct phosphoprotein profiles that can contribute to sex differences in the expression of pathology. Because sex differences in AD-related signaling emerged from this analysis, sex differences in certain phosphorylated proteins within this pathway were validated using western blots. Additionally, sex differences in AD-related neuropathology were further investigated in an AD mouse model that also overexpresses CRF.
MATERIALS AND METHODS Animals
Animals were allocated to experimental groups based on genetic background and sex. Within a specific gene/sex group animals were randomized by selection from different litters. Phosphoproteomic studies and tau western blot studies used adult (460 days) male and female CRF-OE mice and wild-type (WT) littermates purchased from Jackson Laboratories (Bar Harbor, ME, USA). CRF-OE mice were originally generated using a chimeric CRF transgene comprising the mMT-1 promoter driving the rat CRF gene (including introns) and backcrossed onto the C57BL/6 mouse strain. 16 Tissue for western blot studies was taken from mice of different litters than those for phosphoproteomic studies. For analysis of amyloid-β (Aβ) plaques, cognitive function and β-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE-1), Tg2576 mice that express human APP were compared with triple transgenic (TT) mice that both express human APP and overexpress CRF selectively in forebrain. TT mice were generated by crossing Tg2576 mice with Tetop-CRF+ and CaMKII-tTA + mice to obtain the APP+/CRF+/tTA+ (TT) mouse line. 17 In this line, CRF gene expression can be suppressed by doxycycline administration, but doxycycline was not administered in this study so that CRF overexpression in TT mice was maintained throughout life. Care and use of animals was approved by the Children's Hospital of Philadelphia's and Northwestern University's Institutional Animal Care and Use Committee and was in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
Tissue preparation
Phosphoproteomic analysis used tissue (50-70 mg per animal) from the anterior (1.98A/P relative to Bregma) and dorsal (−1.00 mm from the surface of the brain) portions of the cerebral cortex. Samples from three mice from different litters were pooled to yield~190 mg of starting material for each condition (male WT, female WT, male CRF-OE and female CRF-OE). Pooled samples were homogenized, lysed and proteins were precipitated as detailed in Supplementary Methods. A stable heavy lysine 6 (13C6, 97%) isotope labeling of whole mouse (SILAM) reference sample (Cambridge Isotope Laboratories, Tewksbury, MA, USA) was generated by combining one whole SILAM female brain with one whole SILAM male brain. Equal amounts of SILAM reference brain protein were mixed with each cortical protein sample. Samples were digested with trypsin and tryptic peptides were desalted using Sep-Pak tC18 cartridges (Waters, Milford, MA, USA) (Supplementary Methods). Hydrophilic interaction chromatography was used to separate tryptic peptides 18 (Supplementary Methods). Phosphopeptides were enriched from hydrophilic interaction chromatography fractions using immobilized metal affinity chromatography in batch mode (Supplementary Methods).
Mass spectrometry analysis
A hybrid LTQ Orbitrap-Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) coupled with a Nano2D Ultra LC system (Eksigent Technologies, Dublin, CA, USA) and an autosampler analyzed tryptic digests. Raw MS files were processed using MaxQuant (version 3.1.0.5). 19 MaxQuant output files were searched against a mouse protein sequence database comprising reviewed canonical plus isoforms for taxonomy:10090 (Uniprot.org) using an Andromeda search algorithm. The false discovery rate for peptides and proteins was set at 1%. The data were analyzed by log (base 2) transforming SILAC ratios and fitting them to a three-component mixture model based on the approach outlined by Margolin et al. 20 For further details on database searching and statistical analysis see the Supplementary Methods. Phosphopeptides that were significantly different between groups were then analyzed by Ingenuity Pathway Analysis (Qiagen, Redwood City, CA, USA).
AD-related pathology
For Western blots, Aβ plaque quantification and behavior, group sample size was estimated using the sample size and power test in the DOE category of JMP 9.0.0 (2010; SAS) assuming α = 0.05 and power = 0.8. Cortical tissue (n = 5 mice each group) was homogenized and subjected to western blotting. 17, 21 Immunoblots from CRF-OE cortex were probed with a monocolonal antibody to assess paired helical filament-1 (PHF1, 1:1000, V Lee, University of Pennsylvania, Philadelphia, PA, USA). This antibody recognizes tau phosphorylated at Ser 396 /Ser 404 . These phosphorylation sites are two of many on the tau protein associated with various stages of neurofibrillary tangle development in the tauopathy disease process. However, these particular sites are strongly related to late-stage extracellular neurofibrillary tangles, which contain substantial filamentous tau in both AD cases and mouse models of AD. 22 The same blots were probed with antibodies to assess total human tau1 (17025 antibody, 1:1000, V Lee) and a glyceraldehyde-3-phosphate dehydrogenase loading control (1:2,000; Sigma, St. Louis, MO, USA; G9545) (Supplementary Methods). 21 Data were obtained from two blots each containing samples from all groups. Immunoblots from Tg2576 (n = 6 for male and female) and TT (n = 4 for male and female) mice were probed with antibodies directed against BACE-1 (1:1000, R Vassar, Northwestern University, Evanston, IL, USA), pSer 498 -BACE-1 (1:1000; Thermo Fisher Life Technologies, Waltham, MA, USA, PA5-12549) and a β-actin loading control (1:1000; Santa Cruz, Dallas, TX, USA; sc130300). Cleavage of APP by BACE-1 is the initial step in the formation of Aβ. Aβ plaques were evaluated in whole brain sections from TG2576 mice (n = 6 male and 4 female) and TT mice (n = 4 male and female) by two individuals blinded to experimental group using Aβ immunohistochemistry (rabbit anti-Aβ 1:1000; Thermo Scientific, Waltham, MA, USA; 44136; Supplementary Methods). 17 
Spontaneous alternation
Tg2576 (n = 9 male and 22 female) and TT (n = 7 male and 8 female) were placed in the center of a Y-maze (5 × 21 × 15.5 cm 3 ) and allowed to explore the arms for 5 min as described previously. 17 Two trained observers blinded to genotypes recorded the sequence of arm entries. Successful alternation was defined as entry into all three arms in consecutive choices.
RESULTS

Sex differences in CRF-OE phosphopeptide profiles
Our previous findings of sex differences in CRF 1 coupling to Gs and β-arrestin-2 predicted that agonist binding would result in different phosphoprotein profiles, indicative of Gs-related signaling in females and β-arrestin-2 signaling in males. 10 Of the phosphopeptides that could be quantified by having a ratio of the SILAM standard heavy-labeled peptide/light peptide, 5070 were present in both male and female CRF-OE mice ( Supplementary  Table S1 ). Based on the 1% false discovery rate (41.5-fold difference)~15% of these were sexually distinct, with~10% being more abundant in females (FOE phosphoproteome) and 5% being more abundant in males (MOE phosphoproteome) ( Figure 1a ). Phosphopeptide differences were unrelated to overall changes in protein levels, as indicated by an analysis of proteins in cortical samples of these groups that were not enriched for phosphopeptides ( Figure 1b and Supplementary Table S2 ). Of the 5151 proteins quantified based on the identification and quantification of SILAM ratios for two or more lysine-containing peptides unique to each protein, 22 (o 1%) were at least 1.5 times more abundant in female CRF-OE cortex and 25 ( o1%) were more abundant in male CRF-OE cortex based on the same fold difference ( Figure 1b) .
Consistent with sex-biased CRF 1 signaling, MOE and FOE phosphopeptides were overrepresented in functionally distinct pathways as determined by Ingenuity Pathway Analysis (Figure 1c ). MOE phosphopeptides were overrepresented in 12 pathways, five being related to signaling by the small GTPases, Rho and Rac, consistent with a role for β-arrestin-2 in regulating Rho function (Figure 1c and Supplementary Table S3 ). 23 Figure 2a shows roles of those individual phosphopeptides from the MOE phosphoproteome in the Rho signaling pathway. FOE phosphopeptides were less well represented in the Rho A signaling pathway (Figures 1c and 2a) .
As predicted by a female bias towards Gs-dependent signaling, protein kinase A (PKA) signaling was among the top canonical pathways in which FOE phosphopeptides were overrepresented (Figure 1c and Supplementary Table S4 ). Other pathways in which FOE phosphopeptides, but not MOE phosphopeptides, were overrepresented, and that would be predicted by enhanced CRF 1 receptor-Gs association in females, included cyclic AMP and GPCR signaling pathways (Figure 1c and Supplementary Table S4 ). Many pathways in which FOE phosphopeptides were overrepresented, including PKA, contained an insufficient number of phosphopeptides from the MOE phosphoproteome to reach statistical significance for determining overrepresentation (Figure 1c ). Notably, FOE phosphopeptides were highly overrepre-sented in the GABA signaling pathway and MOE phosphopeptides were not present at all, suggesting that CRF overexpression affects cortical GABA signaling in females substantially more than males (Figures 1c and 2b) .
FOE but not MOE phosphopeptides were also overrepresented in an AD-related signaling pathway (Figure 1c ). FOE phosphopeptides converged on two neuropathological processes that contribute to AD, the processing of APP to Aβ that forms plaques and the phosphorylation of microtubule-associated protein tau (MAPT) that is involved in the formation of fibrillary tangles (Figure 2c) . A phosphorylated form of BACE-1 (pSer 498 ), the enzyme that converts APP to the plaque-forming Aβ, 24 was eight times more abundant in the FOE compared with the MOE phosphoproteome. Several kinases in the FOE phosphoproteome regulate tau phosphorylation, a critical step in the formation of fibrillary tangles. 25 Additionally, some of the top canonical pathways in which FOE phosphopeptides are overrepresented are involved in tau phosphorylation including 14-3-3, P70S6K and ephrin signaling. [26] [27] [28] [29] [30] [31] Comparison of male and female WT phosphopeptide profiles A parallel comparison of phosphopeptides that distinguish male and female WT mice (MWT and FWT, respectively) revealed sex differences that were less extensive than those seen in CRF-OE mice. Of 3953 phosphopeptides that could be quantified in both males and females,~9% were more abundant in the FWT and 4% were more abundant in the MWT. Importantly, the top canonical pathways in which phosphopeptides that were more abundant in either sex were overrepresented differed from those that distinguished the FOE and MOE phosphoproteomes (Figure 1d and Supplementary Table S5 ). MWT phosphopeptides were overrepresented in only five canonical pathways ( Supplementary  Table S5 ). With the exception of semaphorin signaling, these were not among the top canonical pathways in which MOE phosphopeptides were overrepresented. Notably, Rho signaling, which distinguished the MOE from the FOE phosphoproteomes, did not distinguish MWT and FWT phosphoproteomes. Although phosphopeptides that were more abundant in FWT compared with MWT were overrepresented in some of the same pathways as were phosphopeptides in the FOE phosphoproteome (e.g., 14-3-3, calcium), they were not overrepresented in many major pathways in which FOE phosphopeptides were overrepresented (e.g., ERK5, PKA, GABA, amyloid signaling), suggesting that most of the distinctions between FOE and MOE result from a sex-genotype interaction (Figure 1d and Supplementary Table S6 ).
Sex differences in AD-related pathology
The finding that phosphopeptides that distinguished female from male CRF-OE mice were overrepresented in AD-related signaling pathways prompted follow-up studies to validate sex differences in AD-related pathology in mouse models. First, MAPT phosphorylation was assessed by western blots of PHF1 in CRF-OE and WT mice. Cortical tissue of female CRF-OE mice had higher PHF1 levels than female WT mice, but there were no differences in PHF1 levels between CRF-OE and WT for males (Figures 3a and b) . Importantly, there were no sex or gene differences in cortical levels of total tau (Tau1) (Figure 3c ). Similar results were obtained with hippocampal tissue (Supplementary Figure S1 ).
Because aging in mouse models of AD-related tauopathy was reported to be associated with increased insoluble phosphorylated tau and decreased soluble phosphorylated tau, insoluble tau was also quantified. 32 Female CRF-OE mice had greater levels of PHF1 in the insoluble fraction compared with WT mice (Figure 3d ). Taken together, these results support the phosphoproteomic findings suggesting that CRF overexpression biases MAPT phosphorylation in females.
Sex differences in aspects of amyloid processing were then evaluated in mice that express human APP without (Tg2576) or with forebrain CRF overexpression (TT mice). In agreement with the phosphoproteomic results, Western blotting of cortical tissue revealed that pSer 498 BACE-1, but not BACE-1 levels, were increased in female TT relative to male TT mice (Figures 4a-c and Supplementary Figures S2A and B) . No sex differences were found in Tg2576 mice (Figures 4a-c) . Figure 4d shows representative Aβ plaques in male and female TT mice. As reported previously, Aβ plaque formation was greater in TT mice compared with Tg2576 mice. 17 Notably, female TT mice had a greater number of plaques compared with all other groups (Figures 4d and e and Supplementary Figure S2 ).
Spontaneous alternation, which is based on the tendency of mice to enter novel arms of a Y-maze, was used to assess shortterm working memory. Female TT rats were impaired compared with all other groups as indicated by a decreased number of corrected alternations (Figure 4f ).
DISCUSSION
This study used the systems biology approach of phosphoproteomics to test a hypothesis generated from receptor immunoprecipitation studies that sex-biased CRF 1 coupling results in the engagement of sexually distinct cellular processes under conditions of excess CRF, similar to those seen in stress-related psychiatric disorders. Supporting this hypothesis, a sexual divergence in the cortical phosphoproteome was identified in CRF-OE mice that was consistent with increased CRF 1 -Gs coupling in females and CRF 1 -β-arrestin-2 association in males. The divergence in the cortical phosphoproteome was due to differential phosphorylation rather than changes in protein expression. That similar sex differences were not apparent in WT mice underscores that they were a product of the interaction between sex and CRF overexpression. The phosphoproteomic data set was further used as a discovery tool to probe the basis of sex differences in disease prevalence, with a focus on AD-related signaling. Increased MAPT and BACE-1 phosphorylation in female mice under conditions of CRF overexpression provided biochemical validation that sex-biased CRF 1 -Gs coupling can enhance signaling involved in the neuropathology of AD. That this may translate to functional sex differences was suggested by enhanced Aβ plaque formation and cognitive impairment seen in female TT mice. Taken together, the results suggest that as a result of sex-biased CRF 1 signaling, excess CRF as seen in stress-related disorders can engage different cellular processes in male and female neurons. These different processes can translate to sex differences in the expression of stress-related neuropathology. AD is an example of one disease in which this mechanism may contribute to female vulnerability.
Sex differences in cell signaling emerging from sex-biased CRF 1 coupling Initial evidence for sex differences in CRF signaling came from physiological studies showing that LC neurons of female rats were more sensitive to CRF and these CRF effects were more sensitive to PKA antagonists in female compared with male rats. 10, 11 Receptor immunoprecipitation studies provided a molecular basis for these functional sex differences by demonstrating greater CRF 1 -Gs association in unstressed females compared with males coupled with decreased stress-induced CRF 1 -β-arrestin-2 association in females compared with males. 10 Because Gs and β-arrestin-2 engage distinct cellular signaling cascades that regulate protein phosphorylation, it was hypothesized that CRF 1 activation would initiate distinct cellular reactions that are expressed as different phosphoproteins profiles in male and female rats. Moreover, these sex differences would be most apparent when CRF is overexpressed, as has been hypothesized to occur in stress-related psychiatric disorders. [7] [8] [9] The current study using a systems biology approach of global phosphoproteomics in a model of CRF overexpression supported this hypothesis. Given that the interaction of CRF with CRF 1 receptors during stress is considered to orchestrate many behavioral, autonomic and endocrine aspects of the stress response, the concept that this will potentially initiate different cellular reactions in males and females has broad implications for sex differences in stress responses and in stressrelated pathology. Using the phosphoproteomic data set to guide discovery, potential disease-related consequences of sex-biased CRF 1 signaling can be examined. The overrepresentation of FOE phosphopeptides in the AD pathway guided our focus on signaling related to this disease.
Sex, CRF-OE and AD Psychosocial and environmental stress have long been considered to be risk factors for AD and thought to accelerate AD progression in vulnerable individuals. 5, 33 Evidence of hypothalamic-pituitaryadrenal dysfunction in AD implicated glucocorticoids as a causal link between stress and AD. [34] [35] [36] [37] However, other studies argue against this and implicated CRF as a more likely causal factor. For example, stress promotion of tau phosphorylation is prevented in mice lacking CRF 1 and in WT mice administered CRF 1 antagonists. 21, 38 Stress-induced enhancement of tau phosphorylation is clinically relevant because hyperphosphorylation of MAPT reduces its association with microtubules, resulting in tau aggregation and the formation of the neurofibrillary tangles that are a hallmark of AD. 39, 40 The comorbidity of AD with psychiatric disorders that are characterized by excessive CRF, such as depression, is also consistent with a causal role for CRF. 37, 41 Similar to these psychiatric disorders, AD is nearly twice as prevalent in females compared to males even when correcting for age. [42] [43] [44] Sex differences in CRF sensitivity as a result of biased CRF 1 -Gs coupling could underlie sex differences in AD vulnerability. This was supported by the present phosphoproteomic analysis, which highlighted two AD-related pathways as distinguishing female and male CRF-OE mice. One pathway involved tau phosphorylation. This was further validated by western blot analysis of cortical tissue that demonstrated that CRF overexpression increased tau phosphorylation on the Ser 396 /Ser 404 residues in female, but not male, CRF-OE mice. The finding that insoluble phosphorylated tau was greater in female CRF-OE mice compared with other groups lends further support to the premise that CRF overexpression in females contributes to AD neuropathology, as increases in insoluble tau may be a better indicator of aging-related neuropathology. 32 Another hallmark of AD is the formation of Aβ plaques. Aβ is formed by the cleavage of APP to the fragment, C99, by BACE, followed by γ-secretase cleavage of C99 to release Aβ. 45 CRF mimics the ability of stress to increase Aβ levels and plaque formation in mouse models of AD, including the Tg2576 mouse used in the present study, and CRF 1 antagonists block the effects of stress in these models. 17, 46, 47 CRF elicits a concentration-dependent secretion of Aβ from primary hippocampal neurons of Tg2576 mice that is mediated by CRF 1 and requires PKA signaling. 47 The PKA dependence of CRF effects on Aβ secretion predicts that this pathway would be favored specifically in females that overexpress CRF. The present demonstration that female TT mice have a greater number of Aβ plaques compared with other groups supports this prediction. This may be attributed to sex differences in levels of pS 498 BACE, which was detected both by the phosphoproteomic analysis and by western blot as being more abundant in the cortex of female mice that overexpress CRF. BACE phosphorylation favors its localization to more acidic intracellular compartments where it is found with higher levels of APP. 48 This leads to the speculation that when CRF is overexpressed, the female bias towards CRF 1 -PKA-related signaling promotes BACE phosphorylation, which biases its cellular localization to compartments where Aβ formation may be accelerated. That this sex difference is functionally relevant was evidenced by both the increased number of plaques in female TT mice and greater cognitive impairment in spontaneous alternation. Although there were no sex differences in phosphorylation of casein kinase-1, an enzyme that phosphorylates Ser 498 -BACE-1, 48 sex differences in activity or expression of CK1 could account for sex differences in Ser 498 -BACE-1 phosphorylation. Notably, CRF can induce Aβ formation in cells through CRF 1 association with γ-secretase and this is dependent on both β-arrestin-1 and β-arrestin-2, as well as CRF 1 -independent mechanisms. 49 The CRF 1 effect mediated by β-arrestins is consistent with other studies supporting a role for β-arrestin-2 in γ-secretase activity and Aβ formation. 50 Sex differences in these effects have not been reported to our knowledge. However, taken with the present findings, this might predict different targets for treating AD based on sex. Taken together, the findings suggest a model whereby, as a result of sexbiased CRF 1 coupling, conditions of elevated CRF in females engage signaling that underlies two AD-related neuropathological processes, tau phosphorylation and synthesis of Aβ ( Figure 5 ). This can account for an interaction between stress and sex that may contribute to female vulnerability to AD. Importantly, the findings suggest that manipulation of CRF 1 -induced PKA signaling may be a potential therapeutic target for slowing the progression of AD, particularly in women.
CONCLUSIONS
The present findings demonstrate that conditions of excessive CRF, which are characteristic of stress-related psychiatric disorders, give rise to sexual differentiation of the cortical phosphoproteome as a result of sex-biased signaling. Distinctions between male and female phosphoproteomes suggest a potential molecular basis for sex differences in stress-related psychiatric and neurodegenerative disorders, such as AD. Our further analysis in an AD model supported the phosphoproteomic results that revealed female vulnerability to CRF-induced AD pathology, and suggested that stress may be a risk factor for AD, specifically in women. Finally, the phosphoproteomic results can be used as a discovery tool, and this unique, rich data set can be mined at more specific levels in future studies to identify how stress and sex intersect to impact selective cellular functions. These explorations will lead to a better understanding of how stress contributes to disease and the determinants of individual vulnerability. 
